Paradigm gets MicroRNA technology licence:
This article was originally published in Clinica
Executive Summary
Paradigm Array Labs, a subsidiary of biotech company Icoria, has secured exclusive rights to MirChip, Rosetta Genomics' proprietary technology for detecting and analysing of microRNA. MicroRNA are small molecules of ribonucleic acid thought to influence a variety of key cellular process: proliferation, apoptosis and metabolism. Using the technology may shed new light on the expression of diseases such as cancer, and help identify important diagnostic markers. Icoria is based at the research triangle park in North Carolina in the US.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.